Read more
5:32 PM · 31 October 2023

Sarepta slumps 40% after disappointing drug trials

-
-
Open account Download free app

Sarepta Therapeutics (SRPT.US) is trading under massive pressure today. Stock is down around 40% on the day, following disappointing results of drug trial. Early evidence suggested that Elevidys drug developed by Sarepta is effective in treatment of patients with Duchenne muscular dystrophy, leading the US Food and Drug Administration to approve its use for a limited number of patients.

However, final trial results that were just published turned out to be disappointing and were not statistically significant to rule the drug effective. As such, Sarepta failed to reach its primary goal, which was broader approval for Elevidys, and missed a chance to boost its sales.

Shares of Sarepta launched today's trading with a big bearish price gap. While part of the drop has been recovered during the cash session, stock is still around 40% lower on the day. A key, multi-year support zone in the $65 per share area is being tested at press time.

Source: xStation5

4 February 2026, 10:41 PM

Alphabet Results: Record Revenues and Investments Showcase the Company’s Dominance!

4 February 2026, 5:55 PM

Tech selloff accelerates❗️US100 dips 2% 📉

4 February 2026, 4:10 PM

India: New battleground of the trade war?

4 February 2026, 3:23 PM

BREAKING🚨US100 decline extends amid inflationary ISM report and tech stocks sell-off

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits